Rubidium chloride rb-82 - Generic Drug Details

What are the generic drug sources for rubidium chloride rb-82 and what is the scope of patent protection?

Rubidium chloride rb-82 is the generic ingredient in two branded drugs marketed by Bracco and Jubilant, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound.

Summary for rubidium chloride rb-82

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	7
What excipients (inactive ingredients) are in rubidium chloride rb-82?	rubidium chloride rb-82 excipients list
DailyMed Link:	rubidium chloride rb-82 at DailyMed

Pharmacology for rubidium chloride rb-82

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Radiopharmaceutical Activity

US Patents and Regulatory Information for rubidium chloride rb-82

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	CARDIOGEN-82	rubidium chloride rb-82	INJECTABLE;INJECTION	019414-001	Dec 29, 1989		RX	No	No
Jubilant	RUBY-FILL	rubidium chloride rb-82	SOLUTION;INTRAVENOUS	202153-001	Sep 30, 2016		RX	No	No

Expired US Patents for rubidium chloride rb-82

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	CARDIOGEN-82	rubidium chloride rb-82	INJECTABLE;INJECTION	019414-001	Dec 29, 1989
Bracco	CARDIOGEN-82	rubidium chloride rb-82	INJECTABLE;INJECTION	019414-001	Dec 29, 1989

Rubidium chloride rb-82 Market Analysis and Financial Projection

Last updated: February 15, 2026

What are the current market dynamics for rubidium chloride Rb-82?

Rubidium chloride Rb-82 is primarily used as a radioactive tracer in positron emission tomography (PET) imaging, particularly for myocardial perfusion studies. The demand for Rb-82 hinges on the expansion of nuclear cardiology procedures, advancements in cardiac imaging, and healthcare system investments.

Key Market Drivers

• Growth in Cardiology Diagnostics: Increasing prevalence of cardiovascular diseases drives demand for non-invasive imaging techniques such as PET scans utilizing Rb-82.
• Technological Advancements: Improvements in PET scanner resolution and the adoption of hybrid imaging systems increase Rb-82's utility.
• Regulatory Approvals: FDA approval (notably for CardioGen-82, a generator system) enhances market access for Rb-82-based diagnostics.
• Healthcare Infrastructure Investment: Rising healthcare spending, especially in North America and Europe, supports increased utilization of nuclear cardiology services.

Market Challenges

• Limited Supply Chain: Short half-life (around 76 seconds) of Rb-82 necessitates proximity to cyclotron facilities, constraining distribution.
• High Costs: Expenses for generators and associated PET facilities limit patient access and market penetration in emerging economies.
• Regulatory and Safety Concerns: Stringent regulations impact manufacturing and distribution, adding to costs and delays.

Market Size and Forecast

• The global nuclear medicine market, which includes Rb-82, was valued at approximately $4.2 billion in 2021.
• Rb-82 accounts for a significant portion of PET radiotracers within this segment.
• The PET radiotracer market is projected to grow at a Compound Annual Growth Rate (CAGR) of around 7% between 2022-2027.
• Rb-82's share is expected to increase as PET becomes preferable over SPECT in cardiac imaging.

How is the financial trajectory structured for Rb-82?

Revenue Streams

• Generator Sales: Production of Rubidium-82 generators (e.g., CardioGen-82 by Bracco) is a primary revenue source.
• Radiotracer Distributions: Distribution of Rb-82 for clinical use involves recurring revenue, dependent on demand volume.
• Service and Maintenance: Support for PET system installation and generator servicing adds incremental income.

Cost Structure

• Generator Manufacturing: Involves costs of Rb-82 production, typically via cyclotron or reactor-based methods.
• Distribution & Logistics: Requires rapid transportation infrastructure due to Rb-82’s short half-life.
• Regulatory Compliance: Significant compliance costs associated with handling radioactive material.

Profitability Outlook

• The profitability of Rb-82-related products depends on production scale, regulatory landscape, and technological adoption.
• Manufacturers with established generator systems benefit from recurring revenue streams.
• Cost efficiency and scaling can improve margins as demand grows.

Investment Trends

• Market players such as Bracco Diagnostics and GE Healthcare are increasing investments in Rb-82 generator technology.
• Emerging markets are exploring local Rb-82 production to mitigate supply chain constraints.
• R&D investment is focused on alternative tracers and improving generator efficiency.

Summary of revenue and cost forecasts (2022–2027)

Year	Estimated Global Rb-82 Market Revenue	CAGR	Remarks
2022	$350 million	7%	Strong adoption in North America, Europe
2023	$375 million	7%	Expansion into Asia-Pacific begins
2024	$402 million	7%	Technologies improve, cost reduction
2025	$431 million	7%	Regulatory environment stabilizes
2026	$462 million	7%	Market penetration increases
2027	$495 million	7%	Dominance in nuclear cardiology evident

Market and financial risks

• Dependency on healthcare reimbursement policies impacts profitability.
• Short half-life constrains logistics, raising operational costs.
• Regulatory changes can delay product approval or increase compliance costs.

Key Takeaways

• The market for Rb-82 is driven by increasing cardiac imaging needs, with growth propelled by technological improvements and healthcare investments.
• Supply chain limitations and costs pose challenges for broad adoption.
• Revenue growth is projected to be at a 7% CAGR, with increased market penetration expected over the next five years.
• The profitability landscape benefits those with efficient generator manufacturing and distribution setups.
• Regulatory environments and logistics infrastructure will significantly influence market expansion.

FAQs

1. What factors influence the pricing of Rb-82 generators?
Generator pricing depends on manufacturing costs, regulatory compliance fees, technological advancements, and market competition. Larger-scale productions and technological efficiencies tend to reduce costs.

2. How does Rb-82 compare to other PET tracers?
Rb-82 is favored for myocardial perfusion due to its rapid clearance and imaging efficiency. However, its short half-life requires proximity to production sites, unlike tracers with longer half-lives.

3. What are the supply chain vulnerabilities for Rb-82?
Its 76-second half-life demands immediate production and distribution, restricting geographical reach. Disruptions in generator manufacturing or transportation can significantly impact availability.

4. Are there emerging markets for Rb-82?
Yes, Asia-Pacific and Middle East regions are investing in nuclear cardiology to meet rising cardiovascular disease burdens, signaling latent growth potential.

5. What regulatory changes could impact Rb-82 markets?
Stricter radiation safety standards, approval processes, or restrictions on radioactive material handling could increase costs and delay market expansion.

---

Sources:

1. MarketsandMarkets. "Nuclear Medicine Market by Product, Application, End User, and Region—Global Forecast to 2027."
2. Bracco Diagnostics. "CardioGen-82 Rb-82 generator official documentation."
3. Frost & Sullivan. "Global PET Radiotracer Market Outlook."
4. U.S. Food and Drug Administration. "Approval of CardioGen-82 for Myocardial Perfusion Imaging."
5. Bloomberg Intelligence. "Pharmaceuticals and Medical Devices Market Data."